

WALLENBERG CENTRE FOR MOLECULAR **AND TRANSLATIONAL MEDICINE**




UNIVERSITY OF

GOTHENBURG


https://doi.org/10.17952/37EPS.2024.P2055



L. I. Beyer, A.-B. Schäfer¹, A. Undabarrena², I. Mattsby-Baltzer³, D. Tietze, E. Svensson¹, A.Stubelius¹, M. Wenzel¹, B. Camara², and A. A. Tietze^{*} University of Gothenburg, Department of Chemistry and Molecular Biology, Wallenberg Centre for Molecular and Translational Medicine, Göteborg, Sweden ¹Chalmers University of Technology, Department of Biology and Biological Engineering, Göteborg, Sweden ²Universidad Técnica Federico Santa María, Laboratorio de Microbiología Molecular y Biotecnología Ambiental, Valparaíso, Chile ³University of Gothenburg, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden



Peptide Design




peptides in their linear and cyclic form were designed and synthesized by automated Fmoc-based solid-phase peptide synthesis (SPPS) and manual on-resin head-to-tail cyclization.


Name	N- terminus	1	2	3	4	5	6	7	8	9	10	11
L1	free	-	DA	$_{D}V$	DA	W	DD	Т	DD	$_{D}V$	-	К
C1	cyclic	-	DA	$_{D}V$	DA	W	DD	Т	DD	$_{D}V$	-	К
L2	free	-	DA	$_{D}V$	DA	W	Orn	Т	Orn	$_{D}V$	-	К
L2-K	free	-	DA	$_{D}V$	DA	W	Orn	Т	Orn	$_{D}V$	-	-
C2	cyclic	-	DA	$_{D}V$	DA	W	Orn	Т	Orn	$_{D}V$	-	Κ
L3	free	W	DA	$_{D}V$	DA	W	Orn	Т	Orn	$_{D}V$	Y(- NO2) ¹	К
L3-K	free	W	DA	$_{D}V$	DA	W	Orn	Т	Orn	$_{D}V$	Y(- NO2)¹	-
С3	cyclic	W	DA	$_{D}V$	DA	W	Orn	Т	Orn	$_{D}V$	Y(- NO2) ¹	К
¹ 3-Nitr	otyrosine											

Secondary


Bioactivity Evaluation



Mode of action studies performed by live cell imaging suggests that these peptides potentially act on the cell membrane via a novel mechanism allowing the passage of small ions resulting in the



Secondary structure analysis was performed by solution NMR spectroscopy using CCPN for NMR assignment and YASARA for structural calculations. The rigidity of the structures are calculated by **RMSD** values.



dissipation of the membrane potential.

MMC₉₉ [µg/mL]

Peptide	S. aureus				E. coli		C. albicans				
	2h	6h	24h	2h	6h	24h	2h	6h	24h		
L1	>	>	>	>	>	>	>	>	>		
C1	>	>	>	>	>	>	>	>	>		
L2	(100) ²	(100) ²	>	>	>	>	50	25	25		
L2-K	>	>	>	>	>	>	>	>	>		
C2	>	>	>	>	>	>	>	>	>		
L3	12.5	12.5	25	12.5	6.3	6.3	12.5	6.3	12.5		
L3-K	25	25	25	50	25	25	25	25	12.5		
C3	>	>	>	> ³	> ³	100	>	>	>		

¹ Minimum microbicidal concentration killing ≥99% of the inoculum (MMC₉₉) at 2, 6, and 24 h of incubation in 100-fold diluted brainheart infusion medium (BHI₁₀₀). Two-fold dilutions series were performed on all peptides, starting at 100 ug/mL. Peptides with a MMC₉₉ of $\leq 100 \mu g/ml$ were repeated on two or four additional occasions (median values are reported). ² Just below 99% killing (98.5%) at 100 µg/mL. ³ MMC₉₉ achieved at 200 µg/mL





Beyer, L., et al., ACS Infect Dis 2024, 10, 79-92.

Vetenskapsrådet

AstraZeneca

For additional information, please contact: Luisa Beyer E-mail: luisa.beyer@gu.se alesia.a.tietze@gu.se

